Summary
All extracted claims are about patents/generic entry and have absent support from the provided FDA label sections (2, 12, 14). No label-based support, contradictions, or safety-relevant alignment can be verified.
Category Scores
Accurate Statements
Unsupported Statements
Farxiga (dapagliflozin) is protected by multiple patents.
No support in the provided label sections (2, 12, 14); those sections contain no information about patents, exclusivity, or IP protection.
“Going off patent” for Farxiga depends on which specific patent or exclusivity protection is meant.
No support in the provided label sections; no discussion of exclusivity/patent-specific timelines.
Patent-by-patent timelines for Farxiga can vary.
No support in the provided label sections.
The earliest expiry usually matters for generic entry.
No support in the provided label sections; no discussion of generic entry or patent expiry.
Follow-on patents can extend protection for specific formulations, indications, or methods.
No support in the provided label sections; no discussion of follow-on patents or extension mechanisms.
Even when a key composition-of-matter patent expires, other patent families may remain in force for Farxiga.
No support in the provided label sections.
Other patent families for Farxiga can be tied to specific dosing forms or strengths.
No support in the provided label sections.
Other patent families for Farxiga can be tied to certain manufacturing processes.
No support in the provided label sections.
Other patent families for Farxiga can be tied to additional protected indications.
No support in the provided label sections.
Other patent families for Farxiga can be tied to related “follow-on” intellectual property.
No support in the provided label sections.
Farxiga’s ability for competitors to market generics (or biosimilars, where applicable) can hinge on the last blocking patent(s), not just the first one to expire.
No support in the provided label sections; no discussion of blocking patents or competitor market timing.
Usually, generics do not launch immediately after the first patent expires for Farxiga.
No support in the provided label sections.
The first patent to expire may not be enough to allow marketing if other patents still block approval or launch for generic versions.
No support in the provided label sections.
The relevant question for Farxiga is which patents are listed as blocking for the specific FDA approval pathway and label.
No support in the provided label sections; no discussion of patent listing or FDA approval pathways.
Patent “expiry” dates from aggregators like DrugPatentWatch.com are a strong starting point for Farxiga launch timing.
No support in the provided label sections; no reference to DrugPatentWatch.com or use of aggregator data.
Actual generic launch timing for Farxiga can be affected by ongoing patent litigation.
No support in the provided label sections.
Actual generic launch timing for Farxiga can be affected by patent listing status.
No support in the provided label sections.
Actual generic launch timing for Farxiga can be affected by FDA regulatory processes.
No support in the provided label sections.
DrugPatentWatch.com tracks relevant Farxiga patents and projected expiry dates.
No support in the provided label sections.
Farxiga’s patent expiration/projection entries on DrugPatentWatch.com can be used to determine an earliest patent expiry date.
No support in the provided label sections.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claims assessed concern intellectual property and generic launch timing rather than drug safety, dosing, contraindications, or warnings in the provided label sections; therefore no direct safety-risk can be attributed from label alignment. However, the claims are entirely unsupported by the provided FDA label sections.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
All extracted claims are about patents/generic entry and have absent support from the provided FDA label sections (2, 12, 14).
Suggested Improvement
Remove or revise patent/IP and generic-launch timing assertions unless supported by the actual FDA label content provided (including any sections that explicitly address exclusivity/patent listing, if present in the full label).